Nanocarrier systems for delivery of siRNA to ovarian cancer tissues

Expert Opinion on Drug Delivery

Volumn 9, Issue 7, 2012, Pages 743-754

  Fathabadi, Eshrat Gharaei ^a   Shelling, Andrew N ^a   Al Kassas, Raida ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

nanoparticles; nonviral nanocarriers; ovarian cancer; siRNA delivery

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; B RAF KINASE; BETA CATENIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBON NANOTUBE; CARBOPLATIN; CHITOSAN; CYANOACRYLATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; LIPID; LIPOFECTAMINE; MAGNETIC NANOPARTICLE; NANOCARRIER; NUCLEAR FACTOR I; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYMER; POLYSACCHARIDE; PROTEIN P53; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; VIRUS VECTOR;

CANCER GENE THERAPY; CANCER TISSUE; CARCINOGENICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE SILENCING; HUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; REVIEW; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

DRUG CARRIERS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC THERAPY; HUMANS; NANOSTRUCTURES; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84862743061     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.683173     Document Type: Review

References (129)

1. Rao DD, Vorhies JS, Senzer N, et al. SiRNA vs.shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-59
2. Numnum TM, Makhija S, Lu B, et al. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol 2008;108:34-41
3. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011;6:1130-46
4. Garson K, Shaw TJ, Clark KV, et al. Models of ovarian cancer-Are we there yet? Mol Cell Endocrinol 2005;239:15-26 (Pubitemid 40848725)
5. Gorringe KL, Campbella IG. Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 2009;3:157-64
6. Vaughan S, Coward JI Jr, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25
7. Kurman RJ, Shih IM. The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am J Surg Pathol 2010;34:433-43
8. Despierre E, Lambrechts D, Neven P, et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol 2010;117:358-65
9. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
10. Vanderhyden BC, Dorward AM. Ovarian cancer and the environment: rodent models. In: McQueen CA. editor. Comprehensive Toxicology. Volume 11 2nd edition. Elsevier Ltd; Elsevier: 2010. p. 483-98
11. Ashworth A, Balkwill F, Bast RC, et al. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum. Gynecol Oncol 2008;108:652-7
12. Maloney A, Clarke PA, Naaby-Hansen S, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007;67:3239-53 (Pubitemid 46724862)
13. Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control 2011;18:8-15
14. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006;32:875-86 (Pubitemid 44469301)
15. Disaia PJ, Bloss JD. Treatment of ovarian cancer:new strategies. Gynecol Oncol 2003;90:S24-32
16. Kieback DJ, Hasenburg A, Runnebaum IB, et al. Gene therapy of ovarian cancer-state of the art and future perspectives. In: Altchek A, Deligdisch L, Kase NG, editors. Diagnosis and Management of Ovarian Disorders. 2nd edition. Elsevier Science; USA: 2003. p. 277-304
17. Sawicki JA, Anderson DG, Langer R. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy. Adv Exp Med Biol 2008;622:209-19
18. Singh P, Joshi S, Russell P, et al. Purine nucleoside phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer. BMC Cancer 2011;11:368
19. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-59 (Pubitemid 40434601)
20. Imamura O, Okada H, Takashima Y, et al. SiRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model. Cancer Lett 2008;268:278-85
21. Kenny GD, Kamaly N, Kalber TL, et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2011;149:111-16
22. Guo P, Coban O, Snead NM, et al. Engineering RNA for Targeted siRNA delivery and medical application. Adv Drug Deliv Rev 2010;62:650-66
23. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007;59:164-82 (Pubitemid 46773052)
24. Tanaka K, Kanazawa T, Ogaw T, et al. Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing. Int J Pharm 2010;398:219-24
25. Bhaskar S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010;7:3
26. Torchilin VP. Nanocarriers for drug delivery: needs and requirements. In: Torchilin VP, editor. Nanoparticulates as Drug Carriers. Imperial College Press; World Scientific: 2006. p. 1-6
27. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-16 (Pubitemid 351413909)
28. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38
29. David S, Pitard B, Benoit JP, et al. Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res 2010;62:100-14
30. He X, Arslan AD, Pool MD, et al. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 2011;30:356-65
31. Liua X, Howard KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007;28:1280-8 (Pubitemid 44816373)
32. Li S, Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007;123:181-3 (Pubitemid 350007827)
33. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed Nanotechnol Biol Med 2009;5:8-20
34. Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv 2008;5:1301-11
35. Jain NK, Nahar M. PEGylated nanocarriers for systemic delivery. Methods Mol Biol 2010;624:221-34
36. Kim PS, Djazayeri S, Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecol Oncol 2011;120:393-403
37. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68
38. Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010;277:4814-27
39. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135-46
40. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine(Lond) 2010;5:523-8
41. Hong S, Lerouell PR, Majoros IJ. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007;14:107-15 (Pubitemid 46124068)
42. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9
43. Martimprey H, Vauthier C, Malvy C, et al. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm 2009;71:490-504
44. Tarapore P, Shu Y, Guo P, et al. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and surviving in ovarian cancers. Mol Ther 2011;19:386-94
45. Chen Q, Butler D, Querbes W, et al. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 2010;144:227-32
46. Cao A, Briane D, Coudert R. Cationic liposomes as transmembrane carriers of nucleic acids. Adv Planar Lipid Bilayer Liposom 2006;4:136-82
47. Kim HK, Davaa E, Myung CS, et al. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 2010;392:141-7
48. Pozo-Rodriguez A, Delgado D, Angeles Solinis M, et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 2010;385:157-62
49. Mevel M, Kamaly N, Carmona S, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release 2010;143:222-32
50. Xue HY, Wong HL. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011;32:2662-72
51. Gao Y, Liu XL, Li XR. Research progress on siRNA delivery with nonviral carriers. Int J Nanomed 2011;6:1017-25
52. Liu Z, Jiao Y, Wang Y, et al. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008;60:1650-62
53. Oh JK, Lee DI, Park JM. Biopolymer-based microgels/nanogels for drug delivery applications. Prog Polym Sci 2009;34:1261-82
54. Lee DW, Yun K, Ban H, et al. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release 2009;139:146-52
55. Cohen JL, Schubert S, Wich PR, et al. Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug Chem 2011;22:1056-65
56. Singh HD, Wang G, Uludag H, et al. Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics. Acta Biomater 2010;6:4277-84
57. Eguchi A, Dowdy SF. SiRNA delivery using peptide transduction domains. Trends Pharmacol Sci 2009;30(7):341-5
58. Lochmann D, Jauk E, Zimmer A. Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm 2004;58:237-51 (Pubitemid 39037232)
59. Choi Y, Lee JY, Suh JS, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010;31:1429-43
60. Hobel S, Loos A, Appelhans D, et al. Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): physicochemical and biological properties of DNA and siRNA complexes. J Control Release 2011;149:146-58
61. Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv 2010;7:1209-26
62. Convertine A, Benoit D, Duvall C, et al. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release 2009;133:221-9
63. Kumar MR, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004;25:1771-7 (Pubitemid 38102253)
64. Felber AE, Castagner B, Elsabahy M, et al. SiRNA nanocarriers based on methacrylic acid copolymers. J Control Release 2011;152:159-67
65. Xu ZP, Zeng QH, Lu GQ, et al. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006;61:1027-40 (Pubitemid 41650188)
66. Ladewig K, Niebert M, Xu Z, et al. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010;31:1821-9
67. Sun C, Lee J, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252-65
68. Figuerola A, Di Corato R, Manna L, et al. From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 2010;62:126-43
69. Li J, Chen Y, Tseng Y, et al. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010;142:416-21
70. Zhang M, Ishii A, Nishiyama N, et al. PEGylated calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA delivery. Adv Mater 2009;21:3520-5
71. Park K. Systemic siRNA delivery using biocompatible calcium phosphate nanoparticles. J Control Release 2010;142:295
72. Kim D, Kim J, Park M, et al. Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles. Biomaterials 2011;32:2593-604
73. Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release 2010;148:122-7
74. Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 2011;149:65-71
75. Patra CR, Bhattacharya R, Mukhopadhyay D, et al. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010;62:346-61
76. Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008;60:1307-15
77. Tanaka T, Godine B, Bhavane R, et al. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm 2010;402:190-7
78. Tanaka T, Mangala LS, Vivas-Mejia PE, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96
79. Bhattarai SR, Muthuswamy E, Wani A, et al. Enhanced gene and siRNA delivery by polycation-modified mesoporous silica nanoparticles loaded with chloroquine. Pharm Res 2010;27:2556-68
80. Cheung W, Pontoriero F, Taratula O, et al. DNA and carbon nanotubes as medicine. Adv Drug Deliv Rev 2010;62:633-49
81. Hossain S, Stanislaus A, Chua MJ, et al. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release 2010;147:101-8
82. Jayakumar R, Chennazhi KP, Muzzarelli RAA, et al. Chitosan conjugated DNA nanoparticles in gene therapy. Carbohydr Polym 2010;79:1-8
83. Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm 2010;399:1-11
84. Lai W, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release 2009;134:158-68
85. Kim T, Jiang H, Jere D, et al. Chemical modification of chitosan as a gene carrier in vitro and in vivo. Prog Polym Sci 2007;32:726-53 (Pubitemid 46977435)
86. Noh SM, Park MO, Shim G, et al. Pegylated poly-L-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release 2010;145:159-64
87. Nafee N, Taetz S, Schneider M, et al. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomed Nanotechnol Biol Med 2007;3:173-83 (Pubitemid 47332344)
88. Tahara K, Sakai T, Yamamoto H, et al. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008;354:210-16
89. Tan ML, Choong P, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009;61:3-12
90. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 2009;71:257-63
91. Duceppe N, Tabrizian M. Factors influencing the transfection efficiency of ultra low molecular weight chitosan/ hyaluronic acid nanoparticles. Biomaterials 2009;30:2625-31
92. Gazori T, Haririan I, Fouladde S, et al. Inhibition of EGFR expression with chitosan/alginate nanoparticles encapsulating antisense oligonucleotides in T47D cell line using RT-PCR and immunocytochemistry. Carbohydr Polym 2010;80:1042-7
93. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461-6 (Pubitemid 40394299)
94. Sudimack BAJ, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-62 (Pubitemid 30122955)
95. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001;6:44-51 (Pubitemid 32156966)
96. Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 2006;58:487-99 (Pubitemid 43928168)
97. Cun D, Jensen DK, Maltesen MJ, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur J Pharm Biopharm 2011;77:26-35
98. Cun D, Foged C, Yang M, et al. Preparation and characterization of poly (dl-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm 2010;390:70-5
99. Young S, Wong M, Tabata Y, et al. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 2005;109:256-74 (Pubitemid 41737269)
100. Zillies J, Coester C. Evaluating gelatine based nanoparticles as a carrier system for double stranded oligonucleotides. J Pharm Pharm Sci 2005;7:17-21 (Pubitemid 41522054)
101. Kushibiki T, Nagata-Nakajima N, Sugai M, et al. Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-h type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds. J Control Release 2006;110:610-17 (Pubitemid 43163451)
102. Ofokansi K, Winter G, Fricker G, et al. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm 2010;76:1-9
103. Zeineldin R, Muller CY, Stack MS, et al. Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010;2010:1-11
104. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264-75
105. Krieger ML, Eckstein N, Schneider V, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 2010;389:10-17
106. Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22
107. Dickerson EB, Blackburn WH, Smith MH, et al. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010;10:1-11
108. Kim SH, Jeong JH, Lee SH, et al. LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem 2008;19:2156-62
109. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008;26:442-9
110. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002;277:46974-9 (Pubitemid 36159202)
111. Scarberry KE, Dickerson EB, McDonald JF, et al. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc 2008;130:10258-62
112. Zhao Y, Zong Z, Xu H. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol 2010;116:563-71
113. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-72 (Pubitemid 351480526)
114. Landen Jr CN, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-08
115. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal Delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006;5:1708-13
116. Mangala LS, Han HD, Berestein G, et al. Liposomal siRNA for Ovarian Cancer. Therapeutic Applications of RNAi: Methods and Protocols. Volume 555 Humana Press, a part of Springer Science Business Media, LLC; New York: 2009. p. 29-42
117. Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24 (Pubitemid 44338579)
118. Rose SL, Kunnimalaiyaan M, Drenzek J, et al. Notch 1 signaling is active in ovarian cancer. Gynecol Oncol 2010;117:130-3
119. Goldberg MS, Xinga D, Ren Y, et al. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci 2011;108:745-50
120. Spannuth WA, Mangala LS, Stone RL, et al. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010;9:2377-88
121. Landen CN Jr, Goodman B, Katre AA, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010;9:3186-99
122. Feo AD, Huang F, Sangodkar J, et al. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer. Model Cancer Res 2009;69:4733-41
123. Ye S, Hao X, Zhou T, et al. Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer 2010;10:611-22
124. Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22
125. Sood AK, Mangala LS, Han H, et al. In vivo angiogenic gene silencing using chitosan nanoparticles in ovarian carcinoma. Gynecol Oncol 2009;112:S2-S185
126. Kim SW, Kim NY, Choi YB, et al. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release 2010;143:335-43
127. Patil ML, Zhang M, Minko T. Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano 2011;5:1877-87
128. Blackburn WH, Dickerson EB, Smith MH, et al. Peptide functionalized nanogels for targeted siRNA delivery. Bioconjug Chem 2009;20:960-8
129. Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy inmultidrug-resistant cancer cells. Small 2009;5:2673-7